Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
International Journal of Medicinal Mushrooms
Impact-faktor: 1.423 5-jähriger Impact-Faktor: 1.525 SJR: 0.431 SNIP: 0.716 CiteScore™: 2.6

ISSN Druckformat: 1521-9437
ISSN Online: 1940-4344

Volumes:
Volumen 22, 2020 Volumen 21, 2019 Volumen 20, 2018 Volumen 19, 2017 Volumen 18, 2016 Volumen 17, 2015 Volumen 16, 2014 Volumen 15, 2013 Volumen 14, 2012 Volumen 13, 2011 Volumen 12, 2010 Volumen 11, 2009 Volumen 10, 2008 Volumen 9, 2007 Volumen 8, 2006 Volumen 7, 2005 Volumen 6, 2004 Volumen 5, 2003 Volumen 4, 2002 Volumen 3, 2001 Volumen 2, 2000 Volumen 1, 1999

International Journal of Medicinal Mushrooms

DOI: 10.1615/IntJMedMushr.v6.i2.10
12 pages

Chemopreventive and Tumoricidal Properties of Ling Zhi Mushroom Ganoderma lucidum (W. Curt.:Fr.) Lloyd (Aphyllophoromycetideae). Part I. Preclinical and Clinical Studies (Review)

Yihuai Gao
Institute of Food, Nutrition and Human Health, Massey University; Landcare Research, Private Bag 92170, Auckland, New Zealand
Wenbo Tank
New Zealand Institute of Natural Medicines, Auckland, New Zealand
He Gao
Division of Traditional Chinese Medicine, New Zealand Institute of Natural Medicines, Auckland, New Zealand
Jin Lan
Institute of Human Nutrition and Department of Biochemistry, Qingdao Medical College, Qingdao University, China
Shufeng Zhou
Division of Pharmacy, School of Life Sciences, Faculty of Science, Queensland University of Technology, Australia; Department of Pharmacy, Faculty of Science, National University of Singapore; University of South Florida FL 33612, USA

ABSTRAKT

There is an increasing interest in identifying effective and safe constituents from medicinal mushrooms for cancer prevention and treatment. Ganoderma lucidum has been used for this purpose, which is given as a single agent, or in combination with herbs or synthetic chemotherapeutic agents. Various polysaccharides (in particular β-D-glucans and glycoproteins) and triterpenoids have been found to be the major active constituents responsible for the chemopreventive and tumoricidal activity of G. lucidum. These compounds exerted promising cancer preventive and anticancer activity in animal (mouse and rat) studies. However, randomized, placebo-controlled, and multicenter clinical studies using G. lucidum have rarely been reported. In a randomized, placebo-controlled clinical study, 38 (26.6%) of 143 cancer patients had stable disease for 12 weeks or more (range, 12−50 weeks) when treated with Ganoply (a G. lucidum polysaccharide extract) orally at 1800 mg three times daily for 12 weeks. Palliative effects on cancer-related symptoms, such as sweating and insomnia, have been observed in many patients. Ganopoly was well tolerated, with five moderate adverse events recorded. These initial findings indicate that G. lucidum may represent a practical and promising approach for cancer prevention and cancer treatment. Further studies are required to establish the relationship between G. lucidum intake dose and cancer risks and to investigate the efficacy and safety when used alone or in combination with chemotherapy.


Articles with similar content:

Anti-Inflammatory and Anti-Cancer Activity of Boswellic Acids from Frankincense (Boswellia serrata Roxb. et Colebr, B. carterii Birdw.)
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 4
Henry Johannes Greten, Thomas Efferth
Medicinal Mushrooms in Human Clinical Studies. Part I. Anticancer, Oncoimmunological, and Immunomodulatory Activities: A Review
International Journal of Medicinal Mushrooms, Vol.19, 2017, issue 4
Solomon P. Wasser
A Phase I/II Study of a Ganoderma lucidum (Curt.: Fr.) P. Karst. Extract (Ganopofy) in Patients with Advanced Cancer
International Journal of Medicinal Mushrooms, Vol.4, 2002, issue 3
Guoliang Chen, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
Hepatoprotective Activity and the Mechanisms of Action of Ganoderma lucidum (Curt.:Fr.) P. Karst. (Ling Zhi, Reishi Mushroom) (Aphyllophoromycetideae) (Review)
International Journal of Medicinal Mushrooms, Vol.5, 2003, issue 2
Yihuai Gao, Min Huang, Zhi-Bin Lin, Shufeng Zhou
A Phase I/II Study of a Ganoderma lucidum (Curt.: Fr.) P. Karst. (Ling Zhi, Reishi Mushroom) Extract in Patients with Chronic Hepatitis В
International Journal of Medicinal Mushrooms, Vol.4, 2002, issue 4
Guoliang Chen, He Gao, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai